EternaTear
Raleigh
About EternaTear
EternaTear is developing a next-generation therapy for the over-the-counter dry eye market. Dry eye is the inability of the tear film and lids to protect the surface of the eye, resulting in itching, burning, and pain. With a dozen or more underlying causes, dry eye is notoriously difficult to diagnose and treat, and if left untreated, it can lead to permanent corneal damage. Patients with even moderate dry eye can suffer from debilitating symptoms that lead to a drastically reduced quality of life. Current treatment options are limited, and most patients rely on over-the-counter eye drops for temporary relief. But because they neither treat the root cause nor appropriately address the symptoms, current products on the market fail to provide adequate relief and must be reapplied as often as 6-12 times every day. By pairing proven technologies with pioneering research, EternaTear™ is developing a product that is closest to natural tears. Using a previously unrecognized mechanism, EternaTear™ can remain on the eye for an extended period of time, reducing the number of applications per day and giving Dry Eye patients lasting relief.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.9M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2020)
- Website: eternatear.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/eternatear-32485 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.